Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 21, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The filing details a specific transaction on March 20, 2006, where 355 Ordinary shares were transferred from the SmithKline Beecham Employee Benefit Trust to a participant in the SmithKline Beecham Unapproved Share Matching Plan. This transaction was notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J Heslop holds an interest in the fund similar to other beneficiaries.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust following the transfer of 355 shares.
- Confirm the specific identity of the participant in the Unapproved Share Matching Plan who received the shares.
- Review the full terms of the SmithKline Beecham Unapproved Share Matching Plan to understand the implications of this transfer.